BlackRock reports 11.3% stake in Harmony Biosciences

BlackRock, Inc. reports beneficial ownership of 6,525,663 shares of Harmony Biosciences Holdings, Inc. common stock, representing 11.3% of the class.

Rhea-AI Filing Summary

BlackRock, Inc. reports beneficial ownership of 6,525,663 shares of Harmony Biosciences Holdings, Inc. common stock, representing 11.3% of the class. BlackRock has sole voting power over 6,445,523 shares and sole dispositive power over 6,525,663 shares, with no shared voting or dispositive power.

The shares are held across certain BlackRock business units, and various underlying persons have rights to dividends or sale proceeds, but no single such person holds more than five percent of Harmony Biosciences’ outstanding common shares.

Key Figures

Beneficial ownership: 6,525,663 shares Percent of class: 11.3% Sole voting power: 6,445,523 shares +3 more

6 metrics

Beneficial ownership 6,525,663 shares Shares of Harmony Biosciences common stock beneficially owned by BlackRock, Inc.

Percent of class 11.3% Portion of Harmony Biosciences common stock class beneficially owned by BlackRock, Inc.

Sole voting power 6,445,523 shares Shares for which BlackRock, Inc. has sole power to vote or direct the vote

Sole dispositive power 6,525,663 shares Shares for which BlackRock, Inc. has sole power to dispose or direct disposition

Shared voting power 0 shares Shares with shared power to vote or direct the vote reported by BlackRock, Inc.

Shared dispositive power 0 shares Shares with shared power to dispose or direct disposition reported by BlackRock, Inc.

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, dispositive power, +1 more

5 terms

beneficially owned financial

"reflects the securities beneficially owned, or deemed to be beneficially owned,"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 6,445,523.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 6,525,663.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

dispositive power financial

"sole power to dispose or to direct the disposition of: 6525663"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"In accordance with SEC Release No. 34-39538 ... this Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Harmony Biosciences (HRMY) shares does BlackRock own?

BlackRock reports beneficial ownership of 11.3% of Harmony Biosciences common stock, totaling 6,525,663 shares. This stake reflects holdings by certain BlackRock business units aggregated under BlackRock, Inc. as the reporting person.

How many Harmony Biosciences (HRMY) shares can BlackRock vote and dispose of?

BlackRock has sole voting power over 6,445,523 shares and sole dispositive power over 6,525,663 shares of Harmony Biosciences common stock, with no shared voting or dispositive power reported.

Who is the reporting person in this Schedule 13G/A for Harmony Biosciences (HRMY)?

The reporting person is BlackRock, Inc.. The filing aggregates securities beneficially owned, or deemed beneficially owned, by certain BlackRock business units and excludes other disaggregated units under applicable SEC guidance.

Do any other investors hold more than 5% of Harmony Biosciences (HRMY) through BlackRock’s accounts?

The filing states that various persons have rights to dividends or sale proceeds from Harmony Biosciences shares held, but that no one person’s interest exceeds five percent of the total outstanding common shares.

What class of Harmony Biosciences (HRMY) securities does BlackRock’s 13G/A cover?

The Schedule 13G/A covers Common Stock of Harmony Biosciences Holdings, Inc., identified by CUSIP 413197104. All reported beneficial ownership, voting power, and dispositive power relate to this class of securities.

Who signed the BlackRock Schedule 13G/A related to Harmony Biosciences (HRMY)?

The report was signed by Spencer Fleming, identified as a Managing Director of BlackRock, Inc. The filing also references Exhibit 24 (Power of Attorney) and Exhibit 99 related to subsidiary identification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 04:47 PM Accepted by SEC EDGAR 07/28/2026 - 04:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Harmony Biosciences Holdings, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

413197104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 413197104

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,445,523.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,525,663.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,525,663.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Harmony Biosciences Holdings, Inc.
(b)	Address of issuer's principal executive offices: 630 W GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 413197104
Item 4.	Ownership
(a)	Amount beneficially owned: 6525663
(b)	Percent of class: 11.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6445523
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6525663
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Harmony Biosciences Holdings, Inc.. No one person's interest in the common stock of Harmony Biosciences Holdings, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/28/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7